CVS Health Stock - Analyst consensus and strategy under scrutiny

CVS Health stock remains closely watched as Wall Street digests recent rating actions and integrates them into a cautious consensus, while investors refocus on the healthcare group's insurance, pharmacy and primary care strategy.

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 17:05 UTC. Details in the imprint.

CVS Health Corp. (US1266501006) remains on Wall Street's radar as analysts reassess the healthcare group's long-term mix of insurance, pharmacy and primary care businesses. Recent rating actions and target moves feed into a cautious but constructive consensus across major houses.

What recent analyst moves show

Analyst sentiment on CVS Health stock has shifted over recent months as earnings pressure from its Medicare Advantage business and pharmacy reimbursement dynamics became clearer. Many houses still rate the stock at Buy or Overweight, but often with trimmed targets.

For example, Morgan Stanley previously raised its price target on CVS Health shares to $111 from $106 while reiterating an Overweight view, arguing that the diversified model and cost actions can support earnings over time. Other firms have emphasized execution risks in Medicare and medical cost trends when framing their stance.

Consensus expectations at a glance

Across Wall Street, the consensus still expects CVS Health to grow earnings per share over the coming years, albeit from a reset base after the 2024 guidance revisions. Estimates generally factor in continued headwinds in Medicare Advantage coupled with stabilization in the pharmacy and retail lines.

Market data providers show that a majority of covering analysts currently list CVS Health with positive ratings, balanced by a minority of Hold recommendations reflecting caution on regulatory and reimbursement uncertainty. Overall, investors get a mixed but broadly constructive analyst picture anchored in the long-term healthcare demand story.

How CVS Health makes its money

CVS Health generates revenue mainly from its health insurance arm Aetna, its pharmacy benefit management business and its nationwide chain of CVS Pharmacy retail stores. In recent years the group has added primary and home-based care capabilities through acquisitions to deepen its integrated care model.

Where the stock trades today

CVS Health stock (US1266501006) trades on the New York Stock Exchange under the ticker CVS; the latest available closing price before publication was about $98 per share in US dollars.

Key facts on CVS Health stock

• Company: CVS Health Corp.
• ISIN: US1266501006
• WKN: 859034
• Ticker: CVS
• Venue: NYSE
• Price (as of 06/18/2026, 15:59 Eastern): 98.26 USD
• Market cap: 122,000,000,000 USD (as of 06/18/2026, based on latest closing price and shares outstanding)
• Sector / Industry: Health Care / Managed Health Care & Drug Retail
• Index membership: Standard & Poor's 500 index
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.